The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice by Xing, R. et al.
This is a repository copy of The effect of the heart rate lowering drug Ivabradine on 
hemodynamics in atherosclerotic mice.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/137285/
Version: Published Version
Article:
Xing, R., Moerman, A.M., Ridwan, R.Y. et al. (6 more authors) (2018) The effect of the 
heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice. Scientific 
reports, 8. 14014. ISSN 2045-2322 
https://doi.org/10.1038/s41598-018-32458-3
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1SCIENTIFIC REPORTS |  (2018) 8:14014 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
ǤǤȀ
ơ



R. X   ?, A. M. Mem ?, R. Y. R ?ǡ ?ǡǤGle ?, E. J. Meee ?ǡ ?,  
Ǥ	ǤǤSee ?, P. C. E ?, F. J. H. Gje ?ƬǤHee ?

ǤǡǡƤơ
Ǥơ
ȋȌǡƪǦ
ǡǦƪǤǡơ
ǤơȋȌ ?
ȋȌǤ−/−
ȋȌǤ	ǡ
ȋ ? ?ȀȀȌ ?ǡ
Ǥǡ
ǤǦ
ǦǤǦǡǤ
Ƥȋ ? ? ?± ? ?Ǥ ? ? ?±  ? ?ǡ< ?Ǥ ? ? ?ȌǤ
ƪƤȋ ? ? ?Ǥ ? ?± ? ?Ǥ ? ?Ǥ ? ?Ǥ ? ?±  ? ?Ǥ ? ?ǡ< ?Ǥ ? ?Ȍǡ
ƪȋ ? ? ?Ǥ ? ?± ? ?Ǥ ? ?Ǥ ? ?Ǥ ? ?±  ? ?Ǥ ? ?ǡ
< ?Ǥ ? ?ȌǤǡǡ
Ǥ
ơ
Ǥ
Atherosclerosis is characterized by the accumulation of lipids, ibrous tissues and inlammatory cells in the arte-
rial wall. he initiation of atherosclerosis is regulated by low wall shear stress (WSS), while high WSS is known to 
be athero-protective in the early phase of the disease1,2. When the disease progresses, the plaques can grow to the 
extent that they afect lumen diameter, resulting in changes in WSS over the plaque3–5. How these changes in WSS 
afect progression of the disease is still a topic under investigation3,4.
Increased heart rate has been established as a risk factor for cardiovascular disease in a healthy population and 
in a population with a history of various heart diseases6–8. he heart rate lowering drug Ivabradine acts on the 
cardiac pacemaker If ion current which is highly expressed in the sinoatrial node. By inhibiting the If current, the 
diastolic depolarization phase is delayed, thus the heart rate is selectively reduced9. Several clinical studies showed 
that Ivabradine improved cardiac outcome in patients who had coronary artery disease with previous heart fail-
ure8,10,11. However, a recent study suggested no beneicial efect of Ivabradine on patients who had coronary artery 
disease without heart failure12. Since the reported results are event-based only, size and composition of these 
coronary artery plaques is unknown, and hence the efect of Ivabradine on plaque progression is not conclusive.
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Experimental evidence of lowering heart rate on reduced plaque burden was previously demonstrated by 
Beere et al.13,14. Animal studies have shown that Ivabradine reduced heart rate and decreased oxidative stress, 
prevented endothelial dysfunction and thus reduced atherosclerosis15–20. hese studies suggested that the efect of 
Ivabradine was exerted via alteration of the hemodynamic environment. However, the mechanism of the benei-
cial efect of Ivabradine on hemodynamics has not been established. We and others suggested that by increasing 
the duration of the diastolic phase and thus lowering the heart rate, Ivabradine indirectly alters the local hemo-
dynamic environment16,21. In our previous study, using LDLR−/− mice, an increased WSS in the aortic arch was 
observed upon treatment with Ivabradine21. WSS was calculated using averaged low measurement from multiple 
mice and using the geometry of one mouse. Also, the efect of Ivabradine on plaque progression and/or compo-
sition was not investigated. Most animal studies focused on the preventive efect of Ivabradine: the animals were 
treated with Ivabradine simultaneously with the onset of high fat diet. his does not relect the clinical situation 
where patients with known cardiovascular disease showed improved secondary outcomes ater Ivabradine treat-
ment8,10,11. In other studies, endothelial dysfunction was irst induced by 4–6 weeks of high fat diet and then 
Ivabradine was administered17,21. However, this duration of high fat diet was too short to induce formation of an 
advanced plaque. herefore, a curative study design where Ivabradine treatment is administered ater the forma-
tion of an advanced plaque is more clinically relevant.
herefore, in this study, we performed a detailed analysis of the efect of Ivabradine on WSS and atheroscle-
rotic plaque progression and composition in a mouse model of atherosclerosis. We used the well-established 
cast mouse model on ApoE−/− mice, in which a plaque with characteristics of a vulnerable phenotype is induced 
upstream of the cast. Ater formation of this plaque, animals were treated with Ivabradine and its efect on blood 
low parameters, WSS, and its potential efect on plaque composition was analyzed.

To study wall shear stress (WSS) in vivo, we need to acquire parameters including mouse-speciic vessel geometry, 
blood low velocity and vessel diameter. he vessel geometry can be obtained using high-resolution micro-CT 
imaging, while blood low velocity and vessel diameter can be assessed using ultrasound imaging. his informa-
tion can then be processed and used to compute WSS.
ǡǤ Female ApoE−/− mice on a C57BL/6 J genetic 
background (n = 18) were purchased from Charles River (Maastricht, he Netherlands). At 13 weeks of age, nor-
mal chow diet was replaced with an atherogenic high fat diet (Altromin Spezialfutter, Germany) and provided ad 
libitum. Cast surgery was performed two weeks later on the animals under isolurane-induced anesthesia5,22,23. A 
constrictive cast with an internal diameter of 400 µm tapering to 200 µm over 1.5 mm was placed around the right 
common carotid artery (RCCA), leading to changes in local WSS environment and subsequent plaque develop-
ment. Five weeks ater the cast placement, mice (n = 9) were treated with Ivabradine in drinking water ad libitum 
for a duration of 2 weeks (162 mg/L, equivalent to 15 mg/kg/day) or with regular drinking water as control (n = 9). 
his optimal dose was determined in our previous publication21, where we demonstrated a biological efect of 
Ivabradine on the arterial wall and a reduction in heart rate by approximately 20%, proportional to that observed 
in Ivabradine-treated patients10.
he amount of drinking water was monitored for mice and refreshed twice a week. A pre-study power analysis 
was performed based on our previous experience with this dose of Ivabradine21, where the smallest signiicant 
biological efect of Ivabradine on the arterial wall was observed in the endothelial VCAM-1 expression in the 
outer curvature of the mouse aorta (reduction by 80% with a standard deviation of 45%). To reach a power of 
80%, 5 experimental animals are required to obtain statistical signiicance (p < 0.05). An estimated 40% loss of 
experimental animals due to the multiple anesthesia moments was incorporated and ethical approval for 9 exper-
imental animals per group was obtained. All animal experiments were performed conform to the guidelines from 
Directive 2010/63/EU of the European Parliament on the protection of animals used for scientiic purposes, and 
were approved by the ethical committee of Erasmus MC Rotterdam.
  Ǥ Doppler Ultrasound Imaging was performed using Vevo 2100 
(VisualSonics). Blood velocity waveform upstream of the RCCA was measured with a 40-MHz transducer in 
the pulse-wave mode. he distinction between the systole and diastole of the cardiac cycle was determined by 
the dicrotic notch identiied on the RCCA blood velocity waveforms24. RCCA diameter at systole or diastole was 
measured in the M-mode at the same location of the velocity measurement, allowing conversion of blood velocity 
(mm/s) to low (mm3/s) assuming a parabolic velocity proile and a circular geometry of the vessel cross-section. 
he parameters were determined at 5 weeks ater cast placement (t = 0, baseline) and 3 days ater the treatment 
of Ivabradine (t = 3) in both control and Ivabradine-treated mice. Animals were anesthetized under isolurane 
(1.5–3% with 1 L/min oxygen) during the measurement while heart rate was measured by ECG during 24–38 min 
ater beginning anesthesia. he body temperature was maintained between 35.8 °C to 37.7 °C during the proce-
dure by a heating pad and a heating lamp.
At t = 3, contrast-enhanced micro-CT imaging was performed using a Quantum FX (PerkinElmer). he scan-
ning parameters used were 90kvp, 160 µA with 20 mm ield of view and a scan duration of 4.5 min. Contrast 
agent eXIA 160 (Binitio Biomedical, Canada) was used with an injection dose of 150 µl/25 grams of body weight. 
Micro-CT imaging was performed directly before the ultrasound imaging. Images in Hounsield unit (HU) were 
reconstructed with an isotropic resolution of 40 µm. However, 7 out of 18 mice died 1–2 days ater the imaging 
point at t = 3. his premature death is probably due to the combination of repeated anesthesia and the use of 
imaging contrast agent. As a result, WSS simulation (n = 5 control and n = 5 Ivabradine-treated mice) and histol-
ogy (n = 4 control and n = 5 Ivabradine-treated mice) analyses were performed in a subset of animals.
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	Ǥ RCCA lumen geometry was segmented 
using previously established protocols in MeVisLab (MeVisLab 2.2.1) and Matlab (Matlab R2017a)25. RCCA 
lumen surface was reconstructed from its origin at the bifurcation of the brachiocephalic artery, to its bifurcation 
into the internal and external carotid artery.
RCCA lumen surface was smoothed using the Vascular Modelling Tool Kit (VMTK 1.2). he superluous ends 
at the proximal and distal side of the vessel surface were clipped and low extensions were added. A volume mesh 
with prism layers was then generated using ICEM (ICEM-CFD 14.5, Ansys) and a mesh-independent solution 
with approximately 580,000 elements was obtained. he Surface area of the RCCA inlet was derived, enabling the 
calculation of location-speciic blood low velocity as an inlet boundary condition.
he Navier-Stokes equations were solved by computational luid dynamics (CFD) using Fluent (Fluent 17.1, 
Ansys). Blood was modeled to be incompressible. A constant viscosity of 3.5 × 10−3 kg·m−1·s−1 was used, and 
vessel wall was assumed to be rigid. A parabolic velocity proile was imposed as inlet boundary condition. he 
time-dependent blood low wave form was derived from Doppler velocity measurements. For the outlet bound-
ary condition, zero pressure was used. Time-dependent low simulations were performed for 2 cardiac cycles with 
100 time steps per cycle. WSS was derived from the computed velocity ield. Finally, post-processing and analysis 
were performed in CFD-Post (CFD-Post 14.5, Ansys) and Matlab to quantify time-averaged WSS (TAWSS), 
TAWSS during systole and diastole, and peak WSS.
Ǥ RCCA vessel samples of Ivabradine-treated mice 
(n = 5) and control mice (n = 4) were harvested and embedded in parain for histological analysis. Serial sections 
of 5 µm thick were collected every 50 µm, from the brachiocephalic bifurcation proximally to the carotid bifurca-
tion distally. he sections were stained with H&E for general plaque morphology, Resorcin-Fuchsin for collagen, 
CD31 for endothelium (1:20, Dianova, Germany) and CD68 for macrophages (1:100, Bio-Rad, USA). Plaque area 
and macrophage area were quantiied (BioPix iQ3.2). Necrotic core was deined as a-cellular, a-nuclear areas, free 
of H&E staining, essentially as described previously5
Ǥ Data analysis was performed in Matlab (Matlab R2017a) and RStudio (RStudio 1.0.153). 
Data are presented as mean ± SD. he normality of the data was evaluated by Shapiro–Wilk test. If the data was 
normally distributed, the student t-test was used for further analyses. For data that was not normally distributed, 
a non-parametric Wilcoxon signed-rank test was used. Diferences between the Ivabradine-treated group and 
the control group were evaluated using an unpaired, two-tailed students’ t-test or Wilcoxon signed-rank test. 
Diferences between the 2 time points (t = 0 vs. t = 3) within the same group were evaluated using a paired, 
two-tailed students’ t-test or non-parametric Wilcoxon signed-rank test. he results were considered signiicant 
if the p-value < 0.05.

Ǥ Heart rate at baseline (t = 0 days) and ater administration of Ivabradine 
(t = 3 days) are shown in Fig. 1A. At baseline, there was no diference in heart rate between the control and the 
treatment group (495 ± 64 bpm vs. 491 ± 83 bpm, p > 0.05). Ater 3 days treatment, heart rate in mice treated 
with Ivabradine was 459 ± 28 bpm, which was signiicantly lower compared to that of the control group (567 ± 32 
bpm, p < 0.001). Interestingly, heart rate in control mice increased signiicantly from baseline to 3 days treatment 
(p < 0.05). he normalized values are listed in Table 1. Compared to the control mice, heart rate of the Ivabradine-
treated mice reduced 18.1%. he data for each individual mouse are presented in the Supplemental Fig. 1.
Ǥ he reduction of heart rate ater the 
administration of Ivabradine resulted in a prolonged cardiac cycle compare to control mice (p < 0.001, data not 
shown). he efect of Ivabradine was further investigated by dividing the cardiac cycle into the systolic and the 
diastolic phase. As shown in Fig. 1B, Ivabradine did not alter the duration of the systolic phase (0.028 ± 0.010 s vs. 
0.029 ± 0.004 s). However, the diastolic phase was signiicantly longer in mice treated with Ivabradine compared 
to that of the control group (Fig. 1C, 0.072 ± 0.008 s vs. 0.096 ± 0.015 s, p < 0.01). Table 1 shows the normalized 
cardiac duration of the systolic and the diastolic phase. he data for each individual mouse are presented in the 
Supplemental Fig. 2.
Figure 1. Diferences of cardiac parameters between control mice (n = 9) and Ivabradine-treated mice (n = 9). 
he graphs are shown as mean ± standard deviation. (A) Heart rate; (B) Duration of the systolic phase; (C) 
Duration of the diastolic phase. Note: *p < 0.05, **p < 0.01, ***p < 0.001.
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ƪǤ he efect of Ivabradine on the low environment 
in the RCCA was studied. here were no diferences in absolute time-averaged or peak blood low between the 
Ivabradine-treated mice and the control mice. However, normalized peak low was 124.2% ± 40.5% ater the 
Ivabradine treatment, while it decreased to 87.3% ± 25.4% in the control group (p < 0.05). he data for each indi-
vidual mouse are presented in the Supplemental Fig 3.
ơǤ Diferent WSS parameters in the 
healthy segment and the plaque segment of the RCCA were investigated. Ater normalization, TAWSS during 
systole in the RCCA was signiicantly higher in animals treated with Ivabradine compared to the control mice 
(Table 2, p < 0.05). Figure 2 illustrates the distribution of TAWSS during systole in the RCCA of a representative 
mouse. Treatment of Ivabradine signiicantly increased TAWSS during systole in both the healthy segment and 
the plaque segment (Fig. 2C). Also, peak WSS increased signiicantly in the upstream RCCA ater the treatment 
of Ivabradine (p < 0.05, Table 2). However, there were no signiicant diferences between the control and the 
Ivabradine-treated mice in terms of the other WSS parameters investigated, including TAWSS or TAWSS during 
diastole. Table 2 summarizes the normalized WSS parameters. he data for each individual mouse are presented 
in the Supplemental Figs 4 and 5.
Ǥ Ater 2 weeks of Ivabradine treatment, RCCA vessel 
samples were harvested for histological analyses. Plaque compositional parameters including plaque area, plaque 
length, relative necrotic core area and relative macrophage area were characterized. None of the parameters were 
signiicantly diferent between the control group and the Ivabradine-treated group (Table 3).

Our study evaluated the efect of Ivabradine on heart rate and its subsequent efect on blood low, WSS and plaque 
composition using a mouse model in which an advanced plaque was present. We demonstrated that Ivabradine 
signiicantly prolonged the duration of the diastolic phase, thus extending the entire cardiac cycle and reducing 
heart rate. Time averaged blood low over the complete heart cycle did not change. Normalized peak blood low 
was signiicantly higher in mice treated with Ivabradine, leading to a signiicant increase in normalized TAWSS 
during systole. hese changes in WSS did not alter the plaque composition ater 2 weeks of Ivabradine treatment.
Heart rate in mice treated with Ivabradine was 18.1% lower than the control mice, comparable to the values 
observed in other studies15–20,26. he control group showed an increase in heart rate. Such an increase was also 
reported by Drouin et al. in dyslipidaemic mice during aging15. his could be due to a combined efect of anes-
thesia and/or the use of contrast agent. To correct for this, we normalized the data to the baseline measurements. 
Ivabradine increased normalized peak blood low in the RCCA to 124.2% ± 40.5% in our mice, which is compara-
ble to the increase we measured in a single murine aorta previously21. In pigs of myocardial ischemia/reperfusion 
model, Heusch et al. reported a 67.5% increase in myocardial blood low ater the administration of Ivabradine27. 
In patients diagnosed with stable coronary artery disease, Ivabradine also induced an increase in low i.e. a 12.4% 
increase in time-averaged peak coronary low velocity during hyperemia. In our study, the increase in systolic 
blood low did result in an increase in TAWSS during systole to 110.7% ± 18.2%, comparable to the increase in 
TAWSS we found previously in the murine aorta21. However, the TAWSS over the entire cardiac cycle was not 
afected by Ivabradine. Based on our current indings and the existing literature, Ivabradine treatment, regardless 
Parameter Control (n = 9)
Ivabradine 
(n = 9) P-value
Heart Rate 116.8% ± 22.1% 95.9% ± 17.2% 0.03*
Systolic Duration 89.5% ± 14.4% 106.4% ± 29.1% 0.14
Diastolic Duration 90.2% ± 22.5% 108.2% ± 31.0% 0.18
Average Blood Flow 90.3% ± 35.9% 125.8% ± 48.5% 0.10
Peak Blood Flow 87.3% ± 25.4% 124.2% ± 40.5% 0.03*
Table 1. Normalized Cardiac and Flow Parameters.
WSS Parameter Control (n = 5) Ivabradine (n = 5) P-value
TAWSS Healthy Segment 77.9% ± 21.2% 99.7% ± 22.9% 0.16
TAWSS Plaque Segment 77.4% ± 21.4% 99.4% ± 23.4% 0.16
TAWSS Systole Healthy Segment 74.6% ± 21.5% 110.7% ± 18.2% 0.02*
TAWSS Systole Plaque Segment 74.1% ± 21.5% 110.7% ± 18.4% 0.02*
TAWSS Diastole Healthy Segment 80.3% ± 20.8% 95.6% ± 24.3% 0.32
TAWSS Diastole Plaque Segment 80.0% ± 21.1% 95.0% ± 24.6% 0.33
Peak WSS Healthy Segment 75.4% ± 22.9% 111.9% ± 22.1% 0.03*
Peak WSS Plaque Segment 74.3% ± 23.1% 111.6% ± 22.9% 0.03*
Table 2. Normalized WSS Parameters.
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of the concentration or duration used, appeared to induce an increase in blood low, but only during systole. his 
increase might be due to an Ivabradine-induced increase in stroke volume, as a prolonged diastolic phase is likely 
to result in an increase in let ventricle volume and thus a larger amount of blood leaving the let ventricle during 
systole. Due to the prolonged duration of diastole, the time-averaged blood low during the complete cardiac cycle 
did not change in our study.
Ivabradine treatment for 6 weeks in LDLR−/− mice resulted in a reduction in endothelial inlammation21, 
suggesting that although the increase in TAWSS is of short duration, it is suicient to afect vascular biology. 
Pre-treatment with Ivabradine has been shown to prevent plaque growth in animal models of atherosclerosis in 
some16,17 but not all20 studies. Custodis et al. and Baumhäkel et al. observed that treatment of mice with Ivabradine 
signiicantly reduced plaque size in the aortic root and/or the ascending aorta16,17. However, it should be noted 
that both studies examined whether Ivabradine could prevent disease (i.e. they started Ivabradine treatment with 
the onset of high fat diet) but the potential efect of Ivabradine on plaque progression was not studied. We wished 
to know whether Ivabradine can be used to treat atherosclerosis and therefore analyzed whether Ivabradine treat-
ment of an existing plaque would afect its composition. his hypothesis was supported by our previous report 
that changes in WSS over a developing plaque afects its phenotype5. However, we did not observe any changes in 
plaque composition in terms of plaque size, length, relative necrotic core area or relative macrophage accumula-
tion in our current study. Our study design with 2 weeks of Ivabradine treatment did not show an efect on plaque 
size or composition. We set out, based on our power calculation, to analyse 5 control versus 5 Ivabradine-treated 
animals. However, due to the premature death of several animals, likely due to the combination of repeated anes-
thesia and the use of imaging contrast agent, we ended up with 4 control versus 5 Ivabradine-treated animals for 
histological analysis. Considering the P values we obtained (ranging from 0.55–0.98, see Table 3) we conclude 
there is no signiicant efect of Ivabradine on the plaque parameters we studied in our model. If we do a power cal-
culation in hindsight, using the lowest p-value found, i.e. p = 0.55 for necrotic core 28.3 ± 10.20 versus 24.3 ± 8.4 
(Table 3), we ind we would need more than a 100 animals to reach statistical signiicance. herefore, our indings 
Figure 2. Ivabradine increased TAWSS during systole. (A) 3D distribution of TAWSS during systole in the 
RCCA before (t = 0) and ater Ivabradine (t = 3) in a representative mouse; (B) Circumferentially-averaged 
WSS along the proximal RCCA; he proximal RCCA was divided into the healthy and the plaque segment, 
indicated by the vertical dashed line; (C) TAWSS during systole in both the healthy and the plaque segments 
were signiicantly increased ater treatment with Ivabradine. Note: ***p < 0.001.
Plaque Composition 
Parameters
Control 
(n = 4)
Ivabradine 
(n = 5) P-value
Plaque Area (mm2) 0.32 ± 0.15 0.32 ± 0.25 0.98
Plaque Length (mm) 0.60 ± 0.28 0.72 ± 0.29 0.76
Necrotic Core (%) 28.3 ± 10.20 24.3 ± 8.4 0.55
Macrophages (%) 40.0 ± 4.5 34.6 ± 13.1 0.79
Table 3. Plaque Composition Parameters.
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point towards a lack of an efect of Ivabradine on plaque size and composition when it is administered ater the 
initiation of disease. hese data are in agreement with the clinical study by Fox et al. who did not observe a bene-
icial efect of Ivabradine on clinical outcome in patients who had coronary artery disease without heart failure12.
In conclusion, Ivabradine led to a small but signiicant increase in low and WSS during the systolic phase of 
the heart cycle. Due to the prolonged diastolic phase, time-averaged low and TAWSS over the complete heart 
cycle did not change. However, increased WSS during the systolic phase only accounts for a short duration of the 
cardiac cycle. his increase did not afect plaque size or composition in our animal model. Previous clinical and 
animal studies showed inconclusive results upon treatment with Ivabradine, with no or a positive efect.

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